Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trialProactive Investors • Tuesday
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsGlobeNewsWire • 09/09/24
Lisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinomaProactive Investors • 09/05/24
Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaGlobeNewsWire • 09/05/24
Lisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMIProactive Investors • 07/27/24
Lisata Therapeutics partners with Haystack Oncology to advance pancreatic cancer therapy researchProactive Investors • 07/18/24
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyGlobeNewsWire • 07/18/24
Lisata Therapeutics completes enrollment in Phase 2a BOLSTER trial for certepetide in bile duct cancerProactive Investors • 07/16/24
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaGlobeNewsWire • 07/16/24
Lisata's certepetide showing promising early results as cholangiocarcinoma treatment – ICYMIProactive Investors • 07/13/24
Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelGlobeNewsWire • 07/10/24
Lisata Therapeutics CEO discusses enrollment milestone for pancreatic cancer trialProactive Investors • 06/18/24
Lisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trialProactive Investors • 06/13/24
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialGlobeNewsWire • 06/13/24
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor EventsGlobeNewsWire • 05/28/24
Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancerProactive Investors • 05/20/24
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic CancerGlobeNewsWire • 05/20/24
Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026Proactive Investors • 05/09/24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24